ProQR Therapeutics N.V. (PRQR)
NASDAQ: PRQR · Real-Time Price · USD
1.990
+0.190 (10.56%)
Apr 14, 2026, 4:00 PM EDT - Market closed
ProQR Therapeutics Revenue
In the year 2025, ProQR Therapeutics had annual revenue of 16.35M EUR, down -16.36%. ProQR Therapeutics had revenue of 4.72M in the quarter ending December 31, 2025, with 6.14% growth.
Revenue (ttm)
16.35M EUR
Revenue Growth
-16.36%
P/S Ratio
10.92
Revenue / Employee
87,605 EUR
Employees
187
Market Cap
209.67M USD
Revenue Chart
* This company reports financials in EUR.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 16.35M | -3.20M | -16.36% |
| Dec 31, 2024 | 19.55M | 10.02M | 105.20% |
| Dec 31, 2023 | 9.53M | 5.17M | 118.51% |
| Dec 31, 2022 | 4.36M | 1.98M | 83.31% |
| Dec 31, 2021 | 2.38M | -7.07M | -74.84% |
| Dec 31, 2020 | 9.45M | 7.52M | 388.98% |
| Dec 31, 2019 | 1.93M | -3.83M | -66.45% |
| Dec 31, 2018 | 5.76M | 4.27M | 285.35% |
| Dec 31, 2017 | 1.50M | -333.00K | -18.22% |
| Dec 31, 2016 | 1.83M | -1.41M | -43.49% |
| Dec 31, 2015 | 3.24M | 2.92M | 933.55% |
| Dec 31, 2014 | 313.00K | 197.00K | 169.83% |
| Dec 31, 2013 | 116.00K | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Karyopharm Therapeutics | 146.07M |
| Codexis | 70.39M |
| Protalix BioTherapeutics | 52.74M |
| Fennec Pharmaceuticals | 44.64M |
| OmniAb | 18.67M |
| Caribou Biosciences | 11.16M |
| Korro Bio | 6.39M |
PRQR News
- 6 days ago - ProQR Highlights Pipeline Expansion and Multiple Upcoming Clinical Catalysts at Investor and Analyst Event - GlobeNewsWire
- 6 days ago - ProQR Announces Partnership with Ginkgo Bioworks and Formation of AI Advisory Board - GlobeNewsWire
- 20 days ago - ProQR to Host Virtual Investor and Analyst Event Highlighting Pipeline on April 8, 2026 - GlobeNewsWire
- 4 weeks ago - ProQR Announces Year End 2025 Operating and Financial Results - GlobeNewsWire
- 6 weeks ago - ProQR Announces Webcast of Presentation at the 2026 Citizens Life Sciences Conference - GlobeNewsWire
- 2 months ago - ProQR Announces Planned Changes to Board Composition - GlobeNewsWire
- 3 months ago - ProQR Announces Encouraging AX-0810 Phase 1 Safety and PK Data, Development Candidate Selections, and 2026 Outlook - GlobeNewsWire
- 4 months ago - ProQR to Participate in 8th Annual Evercore Healthcare Conference - GlobeNewsWire